SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma

Oncotarget

Volumn 5, Issue 20, 2014, Pages 9703-9709

  Wojton, Jeffrey ^a   Meisen, Walter Hans ^a   Jacob, Naduparambil K ^a   Thorne, Amy Haseley ^c   Hardcastle, Jayson ^d   Denton, Nicholas ^a   Chu, Zhengtao ^e   Dmitrieva, Nina ^a   Marsh, Rachel ^a   Van Meir, Erwin G ^f   Kwon, Chang Hyuk ^a,b   Chakravarti, Arnab ^a   Qi, Xiaoyang ^e   Kaur, Balveen ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glioblastoma; Lysosomal dysfunction; SapC DOPS; Synergy; TMZ

Indexed keywords

ANTINEOPLASTIC AGENT; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; SPHINGOLIPID ACTIVATOR PROTEIN C DIOLEOYLPHOSPHATIDYLSERINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; 1,2-DIOLEOYLPHOSPHATIDYLSERINE; ALKYLATING AGENT; DACARBAZINE; NANOMATERIAL; PHOSPHATIDYLSERINE; SPHINGOLIPID ACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CELL CYCLE ARREST; CELL DEATH; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; GLIOBLASTOMA; GLYCOSYLATION; LYSOSOME; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PROTEIN FUNCTION; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; RANDOMIZATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; DACARBAZINE; DRUG SYNERGISM; GLIOBLASTOMA; HUMANS; LYSOSOMES; MICE; MICE, NUDE; NANOSTRUCTURES; PHOSPHATIDYLSERINES; RANDOM ALLOCATION; SAPOSINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930442169     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2232     Document Type: Article

References (19)

1. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K and Delattre JY. Primary brain tumours in adults. Lancet. 2012; 379(9830):1984-1996.
2. Frosina G. DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Molecular cancer research: MCR. 2009; 7(7):989-999.
3. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY and Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA: a cancer journal for clinicians. 2010; 60(3):166-193.
4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-466.
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-996.
6. Krakstad C and Chekenya M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Molecular cancer. 2010; 9:135.
7. Qi X, Chu Z, Mahller YY, Stringer KF, Witte DP and Cripe TP. Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein. Clin Cancer Res. 2009; 15(18):5840-5851.
8. Wojton J, Chu Z, Mathsyaraja H, Meisen WH, Denton N, Kwon CH, Chow LM, Palascak M, Franco R, Bourdeau T, Thornton S, Ostrowski MC, Kaur B and Qi X. Systemic Delivery of SapC-DOPS Has Antiangiogenic and Antitumor Effects Against Glioblastoma. Molecular therapy: the journal of the American Society of Gene Therapy. 2013.
9. Chu Z, Abu-Baker S, Palascak MB, Ahmad SA, Franco RS and Qi X. Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer. PloS one. 2013; 8(10):e75507.
10. Vaccaro AM, Salvioli R, Tatti M and Ciaffoni F. Saposins and their interaction with lipids. Neurochemical research. 1999; 24(2):307-314.
11. Eskelinen EL. Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy. Molecular aspects of medicine. 2006; 27(5-6):495-502.
12. Liaudet-Coopman E, Beaujouin M, Derocq D, Garcia M, Glondu-Lassis M, Laurent-Matha V, Prebois C, Rochefort H and Vignon F. Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer letters. 2006; 237(2):167-179.
13. Hannun YA and Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nature reviews Molecular cell biology. 2008; 9(2):139-150.
14. Van Brocklyn JR. Sphingolipid signaling pathways as potential therapeutic targets in gliomas. Mini reviews in medicinal chemistry. 2007; 7(10):984-990.
15. Boya P and Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene. 2008; 27(50):6434-6451.
16. Hu W, Xu R, Zhang G, Jin J, Szulc ZM, Bielawski J, Hannun YA, Obeid LM and Mao C. Golgi fragmentation is associated with ceramide-induced cellular effects. Molecular biology of the cell. 2005; 16(3):1555-1567.
17. Xu R, Jin J, Hu W, Sun W, Bielawski J, Szulc Z, Taha T, Obeid LM and Mao C. Golgi alkaline ceramidase regulates cell proliferation and survival by controlling levels of sphingosine and S1P. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2006; 20(11):1813-1825.
18. Albertoni M, Shaw PH, Nozaki M, Godard S, Tenan M, Hamou MF, Fairlie DW, Breit SN, Paralkar VM, de Tribolet N, Van Meir EG and Hegi ME. Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene. 2002; 21(27):4212-4219.
19. Bielawski J, Szulc ZM, Hannun YA and Bielawska A. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods. 2006; 39(2):82-91.